Population pharmacokinetics of ethambutol in African children: a pooled analysis. Tikiso, T., McIlleron, H., Abdelwahab, M. T., Bekker, A., Hesseling, A., Chabala, C., Davies, G., Zar, H. J., Rabie, H., Andrieux-Meyer, I., Lee, J., Wiesner, L., Cotton, M. F., & Denti, P. Journal of Antimicrobial Chemotherapy, 77(7):1949–1959, apr, 2022. ![Population pharmacokinetics of ethambutol in African children: a pooled analysis [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Objectives Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high prevalence of HIV or isoniazid resistance. We describe the population pharmacokinetics of ethambutol in children with TB to guide dosing in this population. Methods We pooled data from 188 intensively sampled children from the DATiC, DNDi and SHINE studies, who received 15–25 mg/kg ethambutol daily according to WHO guidelines. The median (range) age and weight of the cohort were 1.9 (0.3–12.6) years and 9.6 (3.9–34.5) kg, respectively. Children with HIV (HIV+; n = 103) received ART (lopinavir/ritonavir in 92%). Results Ethambutol pharmacokinetics were best described by a two-compartment model with first-order elimination and absorption transit compartments. Clearance was estimated to reach 50% of its mature value by 2 months after birth and 99% by 3 years. Typical steady-state apparent clearance in a 10 kg child was 15.9 L/h. In HIV+ children on lopinavir/ritonavir, bioavailability was reduced by 32% [median (IQR) steady-state Cmax = 0.882 (0.669–1.28) versus 1.66 (1.21–2.15) mg/L). In young children, bioavailability correlated with age. At birth, bioavailability was 73.1% of that in children 3.16 years or older. Conclusions To obtain exposure within the 2–6 mg/L recommended range for Cmax, the current doses must be doubled (or tripled with HIV+ children on lopinavir/ritonavir) for paediatric patients. This raises concerns regarding the potential for ocular toxicity, which would require evaluation.
@article{Tikiso2022,
abstract = {Objectives Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high prevalence of HIV or isoniazid resistance. We describe the population pharmacokinetics of ethambutol in children with TB to guide dosing in this population. Methods We pooled data from 188 intensively sampled children from the DATiC, DNDi and SHINE studies, who received 15–25 mg/kg ethambutol daily according to WHO guidelines. The median (range) age and weight of the cohort were 1.9 (0.3–12.6) years and 9.6 (3.9–34.5) kg, respectively. Children with HIV (HIV+; n = 103) received ART (lopinavir/ritonavir in 92{\%}). Results Ethambutol pharmacokinetics were best described by a two-compartment model with first-order elimination and absorption transit compartments. Clearance was estimated to reach 50{\%} of its mature value by 2 months after birth and 99{\%} by 3 years. Typical steady-state apparent clearance in a 10 kg child was 15.9 L/h. In HIV+ children on lopinavir/ritonavir, bioavailability was reduced by 32{\%} [median (IQR) steady-state Cmax = 0.882 (0.669–1.28) versus 1.66 (1.21–2.15) mg/L). In young children, bioavailability correlated with age. At birth, bioavailability was 73.1{\%} of that in children 3.16 years or older. Conclusions To obtain exposure within the 2–6 mg/L recommended range for Cmax, the current doses must be doubled (or tripled with HIV+ children on lopinavir/ritonavir) for paediatric patients. This raises concerns regarding the potential for ocular toxicity, which would require evaluation.},
author = {Tikiso, Tjokosela and McIlleron, Helen and Abdelwahab, Mahmoud Tareq and Bekker, Adrie and Hesseling, Anneke and Chabala, Chishala and Davies, Geraint and Zar, Heather J. and Rabie, Helena and Andrieux-Meyer, Isabelle and Lee, Janice and Wiesner, Lubbe and Cotton, Mark F. and Denti, Paolo},
doi = {10.1093/JAC/DKAC127},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Tikiso et al. - 2022 - Population pharmacokinetics of ethambutol in African children a pooled analysis.pdf:pdf},
issn = {0305-7453},
journal = {Journal of Antimicrobial Chemotherapy},
keywords = {fund{\_}not{\_}ack,original},
mendeley-tags = {fund{\_}not{\_}ack,original},
month = {apr},
number = {7},
pages = {1949--1959},
pmid = {35466379},
title = {{Population pharmacokinetics of ethambutol in African children: a pooled analysis}},
url = {https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac127/6573557},
volume = {77},
year = {2022}
}
Downloads: 0
{"_id":"vRJS6Tn6noNwPEc7b","bibbaseid":"tikiso-mcilleron-abdelwahab-bekker-hesseling-chabala-davies-zar-etal-populationpharmacokineticsofethambutolinafricanchildrenapooledanalysis-2022","author_short":["Tikiso, T.","McIlleron, H.","Abdelwahab, M. T.","Bekker, A.","Hesseling, A.","Chabala, C.","Davies, G.","Zar, H. J.","Rabie, H.","Andrieux-Meyer, I.","Lee, J.","Wiesner, L.","Cotton, M. F.","Denti, P."],"bibdata":{"bibtype":"article","type":"article","abstract":"Objectives Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high prevalence of HIV or isoniazid resistance. We describe the population pharmacokinetics of ethambutol in children with TB to guide dosing in this population. Methods We pooled data from 188 intensively sampled children from the DATiC, DNDi and SHINE studies, who received 15–25 mg/kg ethambutol daily according to WHO guidelines. The median (range) age and weight of the cohort were 1.9 (0.3–12.6) years and 9.6 (3.9–34.5) kg, respectively. Children with HIV (HIV+; n = 103) received ART (lopinavir/ritonavir in 92%). Results Ethambutol pharmacokinetics were best described by a two-compartment model with first-order elimination and absorption transit compartments. Clearance was estimated to reach 50% of its mature value by 2 months after birth and 99% by 3 years. Typical steady-state apparent clearance in a 10 kg child was 15.9 L/h. In HIV+ children on lopinavir/ritonavir, bioavailability was reduced by 32% [median (IQR) steady-state Cmax = 0.882 (0.669–1.28) versus 1.66 (1.21–2.15) mg/L). In young children, bioavailability correlated with age. At birth, bioavailability was 73.1% of that in children 3.16 years or older. Conclusions To obtain exposure within the 2–6 mg/L recommended range for Cmax, the current doses must be doubled (or tripled with HIV+ children on lopinavir/ritonavir) for paediatric patients. This raises concerns regarding the potential for ocular toxicity, which would require evaluation.","author":[{"propositions":[],"lastnames":["Tikiso"],"firstnames":["Tjokosela"],"suffixes":[]},{"propositions":[],"lastnames":["McIlleron"],"firstnames":["Helen"],"suffixes":[]},{"propositions":[],"lastnames":["Abdelwahab"],"firstnames":["Mahmoud","Tareq"],"suffixes":[]},{"propositions":[],"lastnames":["Bekker"],"firstnames":["Adrie"],"suffixes":[]},{"propositions":[],"lastnames":["Hesseling"],"firstnames":["Anneke"],"suffixes":[]},{"propositions":[],"lastnames":["Chabala"],"firstnames":["Chishala"],"suffixes":[]},{"propositions":[],"lastnames":["Davies"],"firstnames":["Geraint"],"suffixes":[]},{"propositions":[],"lastnames":["Zar"],"firstnames":["Heather","J."],"suffixes":[]},{"propositions":[],"lastnames":["Rabie"],"firstnames":["Helena"],"suffixes":[]},{"propositions":[],"lastnames":["Andrieux-Meyer"],"firstnames":["Isabelle"],"suffixes":[]},{"propositions":[],"lastnames":["Lee"],"firstnames":["Janice"],"suffixes":[]},{"propositions":[],"lastnames":["Wiesner"],"firstnames":["Lubbe"],"suffixes":[]},{"propositions":[],"lastnames":["Cotton"],"firstnames":["Mark","F."],"suffixes":[]},{"propositions":[],"lastnames":["Denti"],"firstnames":["Paolo"],"suffixes":[]}],"doi":"10.1093/JAC/DKAC127","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Tikiso et al. - 2022 - Population pharmacokinetics of ethambutol in African children a pooled analysis.pdf:pdf","issn":"0305-7453","journal":"Journal of Antimicrobial Chemotherapy","keywords":"fund_not_ack,original","mendeley-tags":"fund_not_ack,original","month":"apr","number":"7","pages":"1949–1959","pmid":"35466379","title":"Population pharmacokinetics of ethambutol in African children: a pooled analysis","url":"https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac127/6573557","volume":"77","year":"2022","bibtex":"@article{Tikiso2022,\r\nabstract = {Objectives Ethambutol protects against the development of resistance to co-administered drugs in the intensive phase of first-line anti-TB treatment in children. It is especially relevant in settings with a high prevalence of HIV or isoniazid resistance. We describe the population pharmacokinetics of ethambutol in children with TB to guide dosing in this population. Methods We pooled data from 188 intensively sampled children from the DATiC, DNDi and SHINE studies, who received 15–25 mg/kg ethambutol daily according to WHO guidelines. The median (range) age and weight of the cohort were 1.9 (0.3–12.6) years and 9.6 (3.9–34.5) kg, respectively. Children with HIV (HIV+; n = 103) received ART (lopinavir/ritonavir in 92{\\%}). Results Ethambutol pharmacokinetics were best described by a two-compartment model with first-order elimination and absorption transit compartments. Clearance was estimated to reach 50{\\%} of its mature value by 2 months after birth and 99{\\%} by 3 years. Typical steady-state apparent clearance in a 10 kg child was 15.9 L/h. In HIV+ children on lopinavir/ritonavir, bioavailability was reduced by 32{\\%} [median (IQR) steady-state Cmax = 0.882 (0.669–1.28) versus 1.66 (1.21–2.15) mg/L). In young children, bioavailability correlated with age. At birth, bioavailability was 73.1{\\%} of that in children 3.16 years or older. Conclusions To obtain exposure within the 2–6 mg/L recommended range for Cmax, the current doses must be doubled (or tripled with HIV+ children on lopinavir/ritonavir) for paediatric patients. This raises concerns regarding the potential for ocular toxicity, which would require evaluation.},\r\nauthor = {Tikiso, Tjokosela and McIlleron, Helen and Abdelwahab, Mahmoud Tareq and Bekker, Adrie and Hesseling, Anneke and Chabala, Chishala and Davies, Geraint and Zar, Heather J. and Rabie, Helena and Andrieux-Meyer, Isabelle and Lee, Janice and Wiesner, Lubbe and Cotton, Mark F. and Denti, Paolo},\r\ndoi = {10.1093/JAC/DKAC127},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Tikiso et al. - 2022 - Population pharmacokinetics of ethambutol in African children a pooled analysis.pdf:pdf},\r\nissn = {0305-7453},\r\njournal = {Journal of Antimicrobial Chemotherapy},\r\nkeywords = {fund{\\_}not{\\_}ack,original},\r\nmendeley-tags = {fund{\\_}not{\\_}ack,original},\r\nmonth = {apr},\r\nnumber = {7},\r\npages = {1949--1959},\r\npmid = {35466379},\r\ntitle = {{Population pharmacokinetics of ethambutol in African children: a pooled analysis}},\r\nurl = {https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac127/6573557},\r\nvolume = {77},\r\nyear = {2022}\r\n}\r\n","author_short":["Tikiso, T.","McIlleron, H.","Abdelwahab, M. T.","Bekker, A.","Hesseling, A.","Chabala, C.","Davies, G.","Zar, H. J.","Rabie, H.","Andrieux-Meyer, I.","Lee, J.","Wiesner, L.","Cotton, M. F.","Denti, P."],"key":"Tikiso2022","id":"Tikiso2022","bibbaseid":"tikiso-mcilleron-abdelwahab-bekker-hesseling-chabala-davies-zar-etal-populationpharmacokineticsofethambutolinafricanchildrenapooledanalysis-2022","role":"author","urls":{"Paper":"https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkac127/6573557"},"keyword":["fund_not_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh","6GMFi5DCojy3jHY44"],"keywords":["fund_not_ack","original"],"search_terms":["population","pharmacokinetics","ethambutol","african","children","pooled","analysis","tikiso","mcilleron","abdelwahab","bekker","hesseling","chabala","davies","zar","rabie","andrieux-meyer","lee","wiesner","cotton","denti"],"title":"Population pharmacokinetics of ethambutol in African children: a pooled analysis","year":2022}